This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.
Approval for the cobas hpv test. Cobas hpv test indications for use: the cobas hpv test is a qualitative in vitro test for the detection of human papillomavirus (hpv) in patient specimens. The test utilizes amplification of target dna by the polymerase chain reaction (pcr) and nucleic acid hybridization for the detection of 14 high-risk (hr) hpv types in a single analysis. The test specifically identifies types hpv 16 and hpv 18 while concurrently detecting the rest of the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The cobas hpv test is indicated: 1) to screen patients 21 years and older with asc-us (atypical squamous cells of undetermined significance) cervical cytology test results to determine the need for referral to colposcopy; and 2) to be used in patients 21 years and older with asc-us cervical cytology results, to assess the presence or absence of high-risk hpv genotypes 16 and 18. This information, together with the physician¿s assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management. The results of this test are not intended to prevent women from proceeding to colposcopy; 3) in women 30 years and older, the cobas hpv test can be used with cervical cytology to adjunctively screen to assess the presence or absence of high risk hpv types. This information, together with the physician¿s assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management; and 4) in women 30 years and older, the cobas hpv test can be used to assess the presence or absence of hpv genotypes 16 and 18. This information, together with the physician¿s assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management.... (see approval order for additional approval statement detail).
| Device | COBAS HPV TEST |
| Classification Name | Kit, Dna Detection, Human Papillomavirus |
| Generic Name | Kit, Dna Detection, Human Papillomavirus |
| Applicant | Roche Molecular Systems, Inc. |
| Date Received | 2010-06-01 |
| Decision Date | 2011-04-19 |
| Notice Date | 2011-05-06 |
| PMA | P100020 |
| Supplement | S |
| Product Code | MAQ |
| Docket Number | 11M-0300 |
| Advisory Committee | Microbiology |
| Expedited Review | No |
| Combination Product | No |
| Applicant Address | Roche Molecular Systems, Inc. 4300 Hacienda Drive pleasanton, CA 94588-2722 |
| Summary: | Summary of Safety and Effectiveness |
| Labeling: | Labeling |
| Post-Approval Study: | Show Report Schedule and Study Progress |
| Approval Order: | Approval Order |
| Supplement Number | Date | Supplement Type |
|---|---|---|
| P100020 | Original Filing | |
| S054 | 2022-10-21 | 30-day Notice |
| S053 | 2020-07-27 | 30-day Notice |
| S052 | 2020-06-01 | 30-day Notice |
| S051 | 2020-04-17 | 30-day Notice |
| S050 | 2019-09-20 | 30-day Notice |
| S049 | ||
| S048 | 2019-08-08 | 30-day Notice |
| S047 | 2019-04-24 | 30-day Notice |
| S046 | 2019-04-10 | 30-day Notice |
| S045 | 2019-04-08 | 30-day Notice |
| S044 | 2019-04-03 | 30-day Notice |
| S043 | 2019-02-04 | 30-day Notice |
| S042 | 2018-12-14 | 30-day Notice |
| S041 | 2018-11-13 | 30-day Notice |
| S040 | 2018-11-09 | 30-day Notice |
| S039 | 2018-10-25 | 30-day Notice |
| S038 | 2018-08-21 | 30-day Notice |
| S037 | 2018-07-27 | 30-day Notice |
| S036 | 2018-06-29 | 30-day Notice |
| S035 | 2018-06-08 | 30-day Notice |
| S034 | 2018-06-04 | 30-day Notice |
| S033 | 2018-05-23 | 30-day Notice |
| S032 | 2018-05-09 | Real-time Process |
| S031 | 2018-05-04 | 30-day Notice |
| S030 | 2018-04-16 | 30-day Notice |
| S029 | 2018-03-01 | 30-day Notice |
| S028 | 2017-12-07 | 30-day Notice |
| S027 | 2017-10-30 | 30-day Notice |
| S026 | 2017-09-26 | 30-day Notice |
| S025 | 2017-07-28 | Normal 180 Day Track |
| S024 | 2017-07-17 | 30-day Notice |
| S023 | 2017-07-14 | 30-day Notice |
| S022 | 2017-07-14 | 30-day Notice |
| S021 | 2016-09-22 | 30-day Notice |
| S020 | 2016-07-08 | 30-day Notice |
| S019 | 2016-04-18 | 30-day Notice |
| S018 | 2016-04-07 | 30-day Notice |
| S017 | 2015-12-23 | Panel Track |
| S016 | ||
| S015 | 2015-06-24 | 30-day Notice |
| S014 | 2015-03-13 | 30-day Notice |
| S013 | 2015-02-25 | Real-time Process |
| S012 | 2013-11-05 | Real-time Process |
| S011 | 2013-08-14 | 30-day Notice |
| S010 | 2013-08-09 | 30-day Notice |
| S009 | 2013-07-26 | 30-day Notice |
| S008 | 2013-07-01 | Panel Track |
| S007 | 2012-10-09 | 30-day Notice |
| S006 | 2012-08-15 | 30-day Notice |
| S005 | 2012-07-02 | Real-time Process |
| S004 | 2012-04-02 | Normal 180 Day Track |
| S003 | 2012-03-29 | Normal 180 Day Track No User Fee |
| S002 | 2011-12-12 | 135 Review Track For 30-day Notice |
| S001 | 2011-05-31 | Normal 180 Day Track No User Fee |